ClinicaliQ Trial Snapshot
- A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) — Recruiting • Phase III • Neurology • NCT06660394.
- DEEP SEA Study Summary.
- LP352 tested against placebo to reduce seizures in children and adults with Dravet syndrome over 24 months.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months. Conditions: Dravet Syndrome Interventions: LP352, Placebo Lead Sponsor: Longboard Pharmaceuticals Planned Enrollment: 160 participants